Company registration number 10558138 (England and Wales)
GENEDATA LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
GENEDATA LIMITED
COMPANY INFORMATION
Directors
K Teburi
Dr O Pfannes
Secretary
E Hannecart
Company number
10558138
Registered office
James House
Stonecross Business Park
Yew Tree Way
Warrington
Cheshire
WA3 3JD
Auditor
Ernst & Young LLP
One Cambridge Square
Cambridge
CB4 0AE
Business address
Alderley House
Alderley Park
Macclesfield
Cheshire
SK10 4TG
Bankers
Bank of America
2 King Edward Street
London
EC1A 1HQ
GENEDATA LIMITED
CONTENTS
Page
Directors' report
1 - 2
Independent auditor's report
3 - 6
Statement of income and retained earnings
7
Balance sheet
8
Notes to the financial statements
9 - 15
GENEDATA LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Principal activities

The principal activity of the company is that of delivering enterprise solutions for data analytics.

Results and Dividends,

The profit for the year after taxation is £232,561 (2024: £193,173).

The directors do not recommend the payment of a dividend (2024: £nil).

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

K Teburi
Dr O Pfannes
Directors' Insurance and Indemnities

The directors have the benefit of the indemnity provisions contained in the Company's Articles of Association ('Articles'), and the company has maintained throughout the year Directors' and officers' liability insurance for the benefit of the Company, the Directors and its officers. The company is permitted, pursuant to its Articles to provide and maintain qualifying third-party indemnity arrangements for the benefit of all its Directors in a form and scope that comply with the requirements of the Companies Act 2006.

Going concern
After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the foreseeable future. Further detail is provided in note 1.2 to the financial statements.
Post reporting date events

There have been no events occurring after the 31 December 2025 which require adjustment to the disclosure in these financial statements.

Auditor
Ernst & Young LLP were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.
Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard FRS 102 The Financial Reporting standard applicable on the UK and Republic of Ireland ('FRS 102'). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

GENEDATA LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Under applicable law and regulations, the directors are also responsible for preparing a Directors’ report that comply with that law and those regulations. The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company’s website.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
K Teburi
Director
30 June 2026
GENEDATA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GENEDATA LIMITED
- 3 -
Opinion

We have audited the financial statements of Genedata Limited (the 'company') for the year ended 31 December 2025 which comprise the Statement of Income and Retained Earnings, the Balance Sheet and related notes 1 to 12 to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period to 30 July 2027.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company’s ability to continue as a going concern.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

 

We have nothing to report in this regard.

GENEDATA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GENEDATA LIMITED (CONTINUED)
- 4 -

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the Statement of directors’ responsibilities on pages 1 and 2, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations

We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management

GENEDATA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GENEDATA LIMITED (CONTINUED)
- 5 -

Our approach was as follows:

 

A further description of our responsibilities for the audit of the financial statements is located on the

Financial Reporting Council’s website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

 

 

 

GENEDATA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GENEDATA LIMITED (CONTINUED)
- 6 -

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Mark Eilbeck (Senior Statutory Auditor)
For and on behalf of Ernst & Young LLP, Statutory Auditor
Cambridge
30 June 2026
GENEDATA LIMITED
STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
2025
2024
Notes
£
£
Turnover
3
3,306,109
2,795,133
Cost of sales
(2,844,434)
(2,366,775)
Gross profit
461,675
428,358
Administrative expenses
(176,633)
(162,678)
Operating profit
4
285,042
265,680
Interest receivable and similar income
3
15,512
-
0
Profit before taxation
300,554
265,680
Tax on profit
6
(67,993)
(72,507)
Profit for the financial year
232,561
193,173
Retained earnings brought forward
513,915
320,742
Retained earnings carried forward
746,476
513,915
The above results arise from continuing activities.
The Company has no recognised income and expense other than as shown above and therefore no separate statement of other comprehensive income is presented.
The notes on pages 9 to 15 form an integral part of these financial statements.
GENEDATA LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 8 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
7
4,739
651,153
Cash at bank and in hand
1,245,277
227,195
1,250,016
878,348
Creditors: amounts falling due within one year
8
(503,440)
(364,333)
Net current assets
746,576
514,015
Capital and reserves
Called up share capital
10
100
100
Profit and loss reserves
746,476
513,915
Total equity
746,576
514,015

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The notes on pages 9 to 15 form an integral part of these financial statements.
The financial statements were approved by the board of directors and authorised for issue on 30 June 2026 and are signed on its behalf by:
K Teburi
Director
Company registration number 10558138 (England and Wales)
GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
1
Accounting policies
Company information

Genedata Limited is a private company limited by shares incorporated in England and Wales. The registered office is James House, Stonecross Business Park, Yew Tree Way, Warrington, Cheshire, WA3 3JD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the foreseeable future.true

 

Given the primary activity of the company's business is providing business services to other Genedata group companies under transfer pricing arrangements that result in year on year profits, forecasting for going concern purposes is relatively straightforward and based on expected business activity. As a result, the company is dependent on its immediate parent company Genedata AG. Genedata AG has issued a letter of support confirming its continued support of the company for a period to 30 July 2027. The group's requirements for the company's services are relatively unchanged to date and not expected to change significantly in the going concern assessment for a period to 30 July 2027.

 

The company is trading profitably, with positive cashflow and a strong balance sheet. The Company position shows net current assets of £746,576 as at 31 December 2025 (2024: £514,015) and net assets of the same, including a cash balance of £1,245,277 (2024: £227,195). The Company generated a profit before taxation for the year ended 31 December 2025 of £300,554 (2024: £265,680).

 

After making due enquiries and considering expected business activity, the impact of the geopolitical environment, macroeconomic pressure and the strength of the intermediate parent undertaking, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the going concern forecast for a period to 30 July 2027. Accordingly, the financial statements have been prepared on a going concern basis.

1.3
Turnover

Turnover is recognised as the amount receivable for the provision of services when providing clients with software solutions and is shown net of VAT.

1.4
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 10 -
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 11 -
Basic financial liabilities

Basic financial liabilities are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10
Share-based payments

During the year, the Company operated an RSU plan for certain key employees and directors. Under this plan, participants are granted the right to receive shares in the Company at a future date, subject to continuing employment (service conditions) and/or specific performance targets. During the year, 217 restricted stock units (RSU’s) were vested at a fair value of £36,423.

 

GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 12 -
1.11
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

 

2
Judgements and key sources of estimation uncertainty

The preparation of financial statements requires the Company to make judgements, estimates and assumptions about the application of its accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Actual amounts and results may differ from those estimates.

 

Judgements and estimates are evaluated regularly and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Any revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year or prior years, or in the year of the revision and future years if the revision affects both current and future years.

 

In the current year, the Directors do not believe there are any such judgements or estimates that would have a significant effect on the amounts recognised in the current year financial statements.

3
Turnover and other revenue
2025
2024
£
£
Turnover analysed by class of business
Sale of services
3,306,109
2,795,133
2025
2024
£
£
Turnover analysed by geographical market
Europe
3,306,109
2,795,133
2025
2024
£
£
Other revenue
Interest income
15,512
-
4
Operating profit
2025
2024
Operating profit for the year is stated after charging:
£
£
Fees payable to the company's auditor for the audit of the company's financial statements
30,000
8,400
GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 13 -
5
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
26
23

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
2,476,177
1,962,679
Social security costs
236,253
313,696
Pension costs
132,004
105,227
2,844,434
2,381,602
6
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
67,993
68,984
Deferred tax
Adjustment in respect of prior periods
-
0
3,523
Total tax charge
67,993
72,507

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
300,554
265,680
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
75,139
66,420
Adjustments in respect of prior years
219
-
0
Under/(over) provided in prior years
-
0
3,523
Movement in deferred tax not recognised
(7,365)
2,564
Taxation charge for the year
67,993
72,507
GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
6
Taxation
(Continued)
- 14 -

Change in Corporation Tax rate

 

The current main rate of corporation tax in the UK is 25%.

 

The Company is part of the Danaher Corporation group (the “Group”). Pillar Two legislation has been enacted or substantively enacted in certain jurisdictions in which the Group operates.

 

Legislation was enacted in the UK on 11 July 2023 which introduced, as part of Finance (No 2) Act 2023:

 

Both the UK DTT and the UK IIR apply for accounting periods beginning on or after 31 December 2023.

The Group has performed an assessment of the Group’s potential exposure to Pillar Two and it is not anticipated that the IIR will apply in the UK.

The UK satisfies the Transitional Country-by-Country Reporting Safe Harbor (“TCSH”) for financial year ending 31 December 2025 and as a consequence no QDMTT is due.

 

7
Debtors
2025
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
-
0
646,430
Other debtors
3,653
2,187
Prepayments and accrued income
1,086
2,536
4,739
651,153

The amounts owed by group undertakings at 31 December 2024 of £646,430 were repaid in full during the year ended 31 December 2025, resulting in a £nil balance owed at the year end.

8
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
69,703
1,608
Corporation tax
2,677
68,984
Other taxation and social security
67,945
49,320
Other creditors
-
0
35,675
Accruals and deferred income
363,115
208,746
503,440
364,333
9
Retirement benefit schemes

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund. At the balance sheet date the company had outstanding contributions to the scheme amounting to £nil (2024: £35,675).

 

GENEDATA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 15 -
10
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
100 Ordinary shares of £1 each
100
100
100
100
11
Related party transactions

In accordance with FRS 102 Section 33.1A, the company has not disclosed transactions with fellow wholly owned members of the Genedata AG / Danaher group, as it is exempt from doing so.

 

12
Parent company

The immediate and ultimate parent undertakings are Genedata AG and Danaher Corporation respectively.  Danaher Corporation is the smallest and largest group of undertakings preparing consolidated accounts including the accounts of the company. The consolidated financial statements of this group are available to the public and may be obtained from 2200 Pennsylvania Avenue, Suite 800 West, Washington DC 20037, USA.

 

 

2025-12-312025-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.100K TeburiDr O PfannesE Hannecart105581382025-01-012025-12-3110558138bus:Director12025-01-012025-12-3110558138bus:Director22025-01-012025-12-3110558138bus:CompanySecretary12025-01-012025-12-3110558138bus:RegisteredOffice2025-01-012025-12-31105581382025-12-31105581382024-01-012024-12-3110558138core:RetainedEarningsAccumulatedLosses2024-12-3110558138core:RetainedEarningsAccumulatedLosses2023-12-3110558138core:ShareCapital2025-12-3110558138core:ShareCapital2024-12-3110558138core:RetainedEarningsAccumulatedLosses2025-12-3110558138core:RetainedEarningsAccumulatedLosses2024-12-31105581382024-12-3110558138core:ShareCapitalOrdinaryShareClass12025-12-3110558138core:ShareCapitalOrdinaryShareClass12024-12-3110558138core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3110558138core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3110558138core:UKTax2025-01-012025-12-3110558138core:UKTax2024-01-012024-12-311055813812025-01-012025-12-311055813812024-01-012024-12-311055813822025-01-012025-12-311055813822024-01-012024-12-3110558138core:CurrentFinancialInstruments2025-12-3110558138core:CurrentFinancialInstruments2024-12-3110558138bus:OrdinaryShareClass12025-01-012025-12-3110558138bus:OrdinaryShareClass12025-12-3110558138bus:OrdinaryShareClass12024-12-3110558138bus:PrivateLimitedCompanyLtd2025-01-012025-12-3110558138bus:FRS1022025-01-012025-12-3110558138bus:Audited2025-01-012025-12-3110558138bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP